Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted treatments and a clinically documented resistance to chemotherapy. They are significantly enriched in cancer stem cells (CSCs), which makes claudin-low tumor models particularly attractive for studying CSC behavior and developing novel approaches to minimize CSC therapy resistance. One proposed mechanism by which CSCs arise is via an epithelial-mesenchymal transition (EMT), and reversal of this process may provide a potential therapeutic approach for increasing tumor chemosensitivity. Therefore, we investigated the role of known EMT regulators, miR-200 family of microRNAs in controlling the epithelial state, stem-like properties and therapeutic response in an in vivo primary, syngeneic p53 null claudin-low tumor model that is normally deficient in miR-200 expression. Using an inducible lentiviral approach, we expressed the miR-200c cluster in this model and found that it changed the epithelial state, and consequently, impeded CSC behavior in these mesenchymal tumors. Moreover, these state changes were accompanied by a decrease in proliferation and an increase in the differentiation status. miR-200c expression also forced a significant reorganization of tumor architecture, affecting important cellular processes involved in cell-cell contact, cell adhesion and motility. Accordingly, induced miR200c expression significantly enhanced the chemosensitivity and decreased the metastatic potential of this p53 null claudin-low tumor model. Collectively, our data suggest that miR-200c expression in claudin-low tumors offers a potential therapeutic application to disrupt the EMT program on multiple fronts in this mesenchymal tumor subtype, by altering tumor growth, chemosensitivity and metastatic potential in vivo.
INTRODUCTION
Breast cancer is not a single disease, but rather a heterogeneous disease with multiple subtypes. The majority of claudin-low breast cancers are characterized as triple negative, with no amplification of HER2 or expression of estrogen and progesterone receptors, and very poor prognosis. A unique feature of these tumors is lack of cell-cell adherens and tight junction genes, such as E-cadherin and claudins. 1 Loss of these genes is also characteristic of the epithelial-mesenchymal transition (EMT), a process that governs metastatic dissemination, during which cells lose cell-to-cell junctions, breach the basement membrane and disseminate. 2, 3 Accordingly, in-depth characterization of claudin-low tumors revealed a significant overlap between their core genetic profiles and those of cells undergoing EMT. 1, 4, 5 Notably, cells that undergo EMT often acquire properties associated with cancer stem cells (CSCs). 6 Consistently, claudin-low tumors are enriched in functional CSCs. 7 Increasing evidence suggests that treatment resistance of cancers, including breast, is the result of residual CSC subpopulations that are capable of regenerating the epithelial components of a recurring tumor by intrinsic self-renewal mechanisms. 8, 9 Consequently, as claudin-low tumors exhibit properties associated with both EMT and CSC self-renewal, they are highly resistant to conventional radiation and chemotherapy. 7, 8 Several transcription factors are known EMT inducers, including Zeb1/2 and Snail/Slug. 2, 3 These factors bind to the promoter region of E-cadherin (Cdh1) and repress its expression. Downregulation of E-cadherin leads to loss of epithelial characteristics and a significant increase in expression of several mesenchymal markers, such as N-cadherin and vimentin. Importantly, E-cadherin causes decreased cell proliferation through contact inhibition, 10 whereas loss of E-cadherin promotes metastasis by increasing cell motility. 11 Another central regulator of EMT is the microRNA-200 (miR-200) family, which consists of five members that are located in two gene clusters (miR-200c-141 and miR200a-b-429). 12 These miRNAs maintain cells in an epithelial state by forming a double-negative feedback loop with Zeb transcription factors. 13 Pursuant to their role in EMT, miR-200 members also regulate self-renewal capabilities of both normal and breast CSCs, 14 and their expression is lost when cells transition into a stem-like state. 15 Previous studies demonstrated that constitutive overexpression of miR-200 reverses EMT in multiple cancer cell lines; 16, 17 however, these studies almost uniformly constitutively expressed miR-200, and although they uncovered many direct targets of miR-200 and provided insight into its biological functions, the effects of miR-200 expression in primary tumors in an in vivo context have not been fully characterized. Here, we show that induced expression of the miR-200c-141 cluster in an in vivo CSC-enriched claudin-low tumor model, decreased tumor growth and stem cell functionality, and resulted in loss of EMT features, accompanied by an increase in chemotherapeutic sensitivity. The model we utilize was developed by transplanting the p53 null mammary tissue into wild-type recipient Balb/c mice.
18 p53 is frequently mutated in human breast cancers, and confers poor prognosis and chemoresistance. 19 Spontaneously arising p53 null murine mammary tumors showed significant heterogeneity, recapitulating the properties of their human counterparts in subtype clustering. 20 Derived murine claudin-low tumors exhibit a significant overlap in their gene expression profile with human claudin-low breast cancers, as well as the spindloid morphology, and are representative of human claudin-low cancer behavior, as illustrated by their pathology following serial transplantation, maintaining their mesenchymal properties and CSC enrichment. 21, 22 Therefore, they represent an improved syngeneic model to investigate agents that target the EMT pathway and CSC behavior, as we can monitor tumor response in orthotopic sites with an appropriate microenvironment and an intact immune system in a wild-type background, while employing the treatment regime potentially applicable in a clinical setting.
RESULTS

miR-200c induction impairs tumor growth
MiR-200c suppresses progression of multiple tumor models propagated from established cell lines. 16, 23, 24 However, most of these studies focused on reversal of EMT in vitro with constitutive expression of miR-200c before tumor establishment. Any potential clinical application would require miR-200c to be manipulated after tumor diagnosis. To determine the effects of miR-200c expression on established primary tumors in vivo, we used a doxycycline (DOX)-inducible lentiviral vector to express the miR-200c-141 cluster (miR-200c for simplicity) in our genetically engineered transplantable p53 null claudin-low tumor model. 21, 25 This vector allows for visualization of transduced cells by constitutive expression of gree fluorescent protein (GFP). Upon DOX administration, transduced cells upregulate both miR-200c and red fluorescent protein (RFP) allowing us to identify and isolate miR-200c-expressing cells. We confirmed the induction of RFP by fluorescence-activated cell sorting (FACS) and fluorescence microscopy ( Figure 1a) , and the corresponding induction of miR-200c by quantitative PCR (qPCR), as well as miR-141 (Supplementary Figure 1A) . Importantly, the level of miR-200c expression achieved in DOX-treated tumors fell within the range null , non-claudin-low breast cancer subtypes 20 ( Figure 1b) . To determine the effect of miR-200c induction on overall tumor growth, tumor volume was measured daily for duration of DOX treatment. The vehicle-treated group exhibited a high average daily tumor growth (130 mm 3 per day), whereas DOX treatment resulted in a significant reduction (50 mm 3 per day; Figure 1c ). Correspondingly, tumor weight at the end of treatment was significantly lower in the miR-200c-expressing group (Figure 1d) . Notably, DOX treatment did not cause a decrease in tumor growth of non-transduced claudin-low tumors, confirming that the observed growth inhibition was due to miR-200c induction (Supplementary Figure 1B) . Immunofluorescent staining and subsequent quantification of Ki67 revealed that the growth defect is due to a significant decrease in the level of proliferation (Figure 1e ). Moreover, injecting the same number of freshly isolated primary RFP+ (mir200c-induced) or GFP+ (mir200c-deficient) sorted cells into orthotopic sites of wild-type mice revealed a significant decrease in tumor latency in miR-200c-expressing group (Figure 1f) . These data further confirm that cells with high expression of miR-200c exhibit decreased proliferation in vivo.
Induced expression of miR-200c reverses EMT in vivo
One hallmark of claudin-low tumor phenotype is the spindloid nature of tumor cells, underlining their EMT characteristics. After inducing expression of miR-200c, we observed a change in morphological properties that suggested a reversal of EMT, as hematoxylin and eosin (H&E) staining showed that tumor cells lost their mesenchymal features, and seemed to switch into a more organized epithelial phenotype (Figure 2a ). Consistent with this phenotypic change, we observed a significant induction of E-cadherin mRNA and protein levels by qPCR and reverse phase protein array (RPPA) analyses, respectively (Figure 2b ). Of note, RPPA showed no change in E-cadherin levels in DOX-treated tumors when they were transduced with a control lentivirus expressing a luciferase reporter rather than miR-200c, confirming that these changes were dependent on miR-200c expression. Surprisingly, no difference in vimentin mRNA levels was detected between DOX-treated and untreated tumors (Figure 2c 
Induced expression of miR-200c enhances differentiation of claudin-low tumors in vivo
Previous studies revealed low expression of basal and luminal lineage markers in claudin-low tumors, highlighting their undifferentiated state. 22 To investigate whether reversal of EMT by miR-200c induction affected the differentiation profile of this claudin-low tumor model, we performed immunostaining for well-known keratin markers of basal and luminal lineages. Indeed, we found that DOX treatment led to an increase in expression of basal marker keratin-14 (K14) that co-localized with increased expression of luminal marker keratin-8 (K8), as seen by double-immunofluorescence staining (Figure 4a ), as well as single staining shown in Supplementary Figure 1D . In addition, upregulated K8 expression was observed primarily in cells with low vimentin expression, based on immunofluorescence analysis of sorted GFP+ and RFP+ cells (Supplementary Figure 1E) .
To further investigate the effects of miR-200c expression on the differentiation of claudin-low tumors, we performed a microarray analysis on sorted GFP+ and RFP+ primary cell populations and compared their overall differentiation scores. The transcriptional similarity of tumors to normal mammary cell populations, referred to as the differentiation score, 1 was determined for our claudinlow tumor model, with and without miR200, and compared with the scores of multiple murine subtypes of breast cancer. 21 Low differentiation scores indicate a similarity to adult mammary stem cells, medium scores a similarity to luminal progenitor cells and higher scores a similarity to mature luminal cells. (Figure 5a ), previously shown to be direct targets of miR-200c, and increased levels of the differentiation markers Elf5 and Gata3 (Figure 5b ), in further support for the role of miR-200c in promoting a more differentiated cell state with a concomitant decrease in stem-like cell properties. Next, we analyzed tumor cells by FACS, using the cell surface antigens CD24 and CD29 to identify the CSC-enriched population (CD24 high /CD29 high ). 22 FACS analysis revealed a change in overall profile and a decrease in the number of double-positive cells in tumors with miR-200c expression, suggesting a reduction in CSCs (Figure 5c ).
To validate the decrease in CSC frequency observed by FACS, we also performed functional assays to measure CSC activity. First, we evaluated the mammosphere-forming efficiency after DOX administration. Notably, we found a significant decrease in the number and size of mammospheres formed in the miR-200c-induced group, demonstrating that miR-200c significantly impairs CSC functionality in claudin-low tumors ( Supplementary Figure 2A and B). To confirm these findings in vivo, we performed a limiting dilution transplantation assay, which is the standard method to determine the in vivo repopulating ability, or CSC frequency of cells after transplantation. We injected decreasing numbers of GFP+ and RFP+ sorted cells into recipient mice, with continued DOX administration, and evaluated the number of resulting tumors. Consistent with the results of the mammosphere assay, we found that miR-200c expression significantly reduced CSC frequency and repopulation potential of primary tumor cells (Figure 5d ). These data validate that stem cell functionality is severely impaired after miR-200c induction in claudin-low tumors.
Chemotherapy resistance is compromised in tumors expressing miR-200c
The claudin-low subtype of breast cancer is highly resistant to conventional chemotherapy, and a claudin-low signature was observed in residual chemotherapy-resistant breast cancer. 7 In this study, miR-200c expression markedly decreased CSC functionality of these tumors, and enhanced their differentiation. Therefore, we evaluated whether it also sensitized tumors to chemotherapy drug carboplatin. To this end, we applied either combination or single agent treatment for a course of 10 days. Although DOX treatment alone led to a decrease in tumor growth, combination treatment with DOX and carboplatin caused complete tumor stasis, with a significantly lower growth rate than the other groups (Figure 6a ). In addition, the final change in tumor volume was significantly decreased in combination-treated group as compared with all other treatment groups ( Figure 6b ). As claudin-low tumors are resistant to single carboplatin treatment because of high percentage of CSCs, 26 we hypothesized that combination of DOX and carboplatin led to the death of miR-200c-expressing cells, as these had diminished CSC functionality. Accordingly, we performed FACS analysis using Annexin V staining to determine the extent of apoptosis in treated tumors. After combination treatment, there was a 10-fold increase in the level of apoptosis compared with untreated mice. This observation was further strengthened by the fact that combination treatment eliminated the miR-200c-expressing cells, as seen by a decrease in the total number of RFP+ cells. Indeed, almost half of the RFP+ cells were Annexin V-positive and were, therefore, undergoing apoptosis (Figure 6c and d) . Of note, miR-200c induction alone lead to an increase in cell death; however, this phenotype is amplified by carboplatin addition. Further H&E analysis showed that these cells were undergoing mitotic catastrophe, as seen by a significantly higher number of giant, multinucleated cells 27 in tumors that had undergone combination treatment, compared with normal mitosis of vehicle-treated tumors (Supplementary Figure 3A) . In addition, combination treatment led to an increase in collagen deposition in tumors, as noted by Mason's Trichrome staining (Supplementary Figure 3B) , presumably due to the wound healing response that occurred in response to the high level of cell death. Taken together, our data suggest that re-expressing miR-200c in 51 where Myc, Erbb2 and Neu tumors are of luminal subtype clustering, and p53null-basal, class 14 and C3-tag cluster into the basal subtype. (c) Microarray analysis also revealed a significant change in 1457 genes, with 562 genes being downregulated and 895 genes being upregulated after treatment with DOX. The microarray analysis was performed on RNA extracted from GFP+ or RFP+ cells sorted from primary tumors, and the heatmap depicts genes with a 0% FDR. The analysis was consistent with a reversal of EMT, as many of the genes found to be downregulated are associated with the mesenchymal state, such as FoxC2, and also confirmed the induction of several keratin markers. (d) The graph indicates the top 12 most significantly enriched gene ontology terms in the 895 miR-200c upregulated gene set. Importantly, most of them were related to terms describing cell-to-cell adhesion and motility. DAPI, 4'-6-diamidino-2-phenylindole.
therapy-resistant tumors leads to chemosensitization by increasing their susceptibility to chemotherapy-induced cell death.
MiR-200c induction decreases metastasis
Metastasis is strongly correlated with angiogenesis in primary tumors. [28] [29] [30] Thus, considering that miR-200 members have been reported to control the levels of pro-angiogenic factors in several cancer models, 31, 32 we next investigated whether miR-200c induction affected pro-angiogenic factors in our model. Although we observed no change in VEGFR protein levels, we found a significant loss of a prominent metastasis-related protein PDGFRβ in RFP+ compared with GFP+ sorted primary tumor cells (Supplementary Figure S3C) . Importantly, PDGFRβ expression correlates with breast cancer aggressiveness and metastasis in human patients, and coincides with EMT-associated metastasis in transgenic mice. 33 
DISCUSSION
Given the central position of the miR-200 family in the process of EMT, restoration of its expression has a tremendous impact on mesenchymal and stem-like properties of cells. 15, 16, 34, 35 Although it was previously shown that miR-200c overexpression reduces mesenchymal features in several in vitro immortalized cell lines, this study for the first time utilized an in vivo primary syngeneic tumor model of breast cancer that has a gene expression signature, which parallels those of human claudin-low tumors. In addition, several studies confirmed that this model closely mimics human claudin-low tumors in their pathology and CSC enrichment. 1, 20, 21 Here, we demonstrate that induced expression of the miR-200c cluster in vivo altered underlying CSC features of claudin-low tumors, making them more sensitive to chemotherapy and dampening their metastatic potential. These effects were achieved through EMT reversal, decreases in proliferation and stem cell functionality, and ultimately, an enhanced susceptibility to cell death.
First, we showed that induction of miR-200c pushed tumor cells into more organized epithelial-like structures and significantly reduced their proliferation. These changes were accompanied by an increase in differentiation score, suggesting a change in stem cell context. Since more differentiated tumors are thought to originate from cells that have more limited progenitor potential, they display less therapy resistance and tumor recurrence 9,36 than human and mouse CSCs. 7, 37, 38 Indeed, our results conclusively showed that miR-200c-expressing tumors had a significant decrease in frequency, as well as functional self-renewing potential of CSCs, shown by limiting dilution transplantation, and that they do not transition into a more proliferative epitheliallike CSC state, as suggested by a recent study. 39 Importantly, the change in CSCs observed upon miR-200c re-expression led to their heightened sensitivity to carboplatin. Accordingly, miR-200c-expressing cells also showed a significant reduction in expression of stem cell markers Ezh2 and Bmi1, shown previously to be direct targets of miR-200. 14, 40, 41 Interestingly, previous studies demonstrated that knockdown of these proteins decreases breast CSC frequency and increases their sensitivity to therapy. 40, 42, 43 Our data support the concept that miR-200c, potentially via its regulation of Ezh2 and Bmi1, can influence functionality and frequency of CSCs in vivo, a finding that could be exploited to overcome therapy resistance manifested in CSC-enriched tumors. Furthermore, significant loss of Zeb1 protein upon miR-200c reexpression suggests a potential decrease in DNA repair capacity, 44 which may in turn increase the susceptibility of miR-200c-induced tumors to chemotherapy.
MiR-200c plays a central role in preventing EMT; thus, it is considered to be anti-metastatic within primary tumors. Nonetheless, there is considerable controversy regarding its role in promoting metastatic growth at the secondary tumor site. Some studies suggested that, although the promotion of EMT increases the intravasation potential of cancer cells, reversal of EMT, or MET, must occur at secondary sites for cells to be able to revert into the epithelial state in the distant organ and form macrometastases. 17, 45 However, these were performed with miR-200 overexpressing tumor cell lines before injecting them into the tail vein, or from the orthotopic site, where they grew with high miR-200c expression. Another study showed that high miR-200c levels in lung tissue correlate with higher metastatic burden and poorer prognosis. 46 However, this result was observed only in luminal subtypes of breast cancer, whereas basal-like breast cancer exhibited worse survival with decreased miR-200c expression. 31 In support of these data, high miR-200 levels were also found to be anti-metastatic in triple-negative breast cancer cells transplanted into an orthotopic site of mouse mammary glands. 47 Unfortunately, our p53 null claudin-low model is not suitable for investigation of metastasis from the orthotopic site, as it is not feasible to detect distant metastasis before killing the animals. Alternatively, we resected the primary tumors early during tumor progression, but after several months no metastases were observed in either of the groups, vehicle or DOX treated. An immune T-cell response to claudin-low tumors in syngeneic mice may inhibit intravasation in this model. However, our tail-vein Multiple RNA interference therapeutics are currently being tested in clinical trials, and several groups have already reported in vivo microRNA delivery using nanoparticles with very promising results. 48 Hence, our studies offer a potential target of microRNA delivery for clinical treatment of an aggressive subtype of breast cancer that is otherwise highly resistant to conventional radiation and chemotherapy. Success of these therapeutic approaches will depend upon improvements in both efficiency and specificity of these delivery systems. In this study, we demonstrate that miR-200c has therapeutic effects in an in vivo model of claudin-low breast cancer, which should provide the basis for clinical applications in miR-based drug development to treat this subtype of breast cancer. Finally, the detailed characterization of this transplantable in vivo model provides the foundation for future studies in which the interplay of EMT and the immune system can be investigated in therapeutic response and metastasis, something that has not been feasible to date using the current cell line and xenograft models.
MATERIALS AND METHODS
Lentiviral vector construction
The DOX inducible vector was a kind gift from Dr Thomas Westbrook at the Baylor College of Medicine. 25 The small hairpin RNA sequence was excised and replaced with the human pre-miR-200c-141 sequence, kindly provided by Dr Gregory Goodall, University of Adelaide, Australia.
Lentiviral infection, tumor digestion and transplantation
Claudin-low tumors from the p53 null mouse tumor bank 20 were digested into single cells according to our laboratory protocol (see below), transduced with the lentivirus containing the insert at an MOI of 20, as previously described, 49 and injected into the cleared fat pad of wild-type Balb/c recipient mice. Detailed protocols can be found at the following website addresses: https:// mediasrc.bcm.edu/documents/2014/bc/tumorpropagationfreezingprotocol.pdf and https://mediasrc.bcm.edu/documents/2014/70/lentiviralproductionand titering.pdf. Tumors were harvested after they reached approximately 1000 mm 3 and again digested into single cells. Cells were analyzed and sorted for GFP positivity. Ten thousand GFP+ cells were injected into the cleared fat pads of host mice. Upon tumor palpability, the mice were randomized into treatment groups. GFP+ tumors were frozen in Dulbecco's modified Eagle's media containing 10% dimethyl sulfoxide and 10% fetal bovine serum for future transplants. Treated tumors were digested and sorted for GFP+ and RFP+ cells. Sorted cells were washed in PBS and either flash frozen in liquid nitrogen for RNA or protein isolation, or injected back into host mice at different dilutions for the limiting dilution transplantation assay. Limiting dilution analysis was performed using the ELDA program. 50 All cell injections and surgeries were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal protocols were reviewed and approved by the Animal Protocol Review Committee at Baylor College of Medicine. Balb/c mice were obtained from Harlan Laboratories. 
Metastasis assay
A total of 30 000 GFP+ cells were injected into the tail veins of 8-to 10-week-old Balb/c mice and DOX treatment was initiated 16 h post injection. The lungs were collected after 8 weeks of treatment, and fixed in 4% paraformaldehyde overnight for histological assays.
DOX and carboplatin treatment DOX (Clontech 631311) was administered to mice in water, using 5% sucrose as the vehicle. DOX solution of 2 mg/ml was freshly prepared twice a week. Carboplatin (MP Biomedicals, 198873) was resuspended in 0.9% NaCl and i.p. injected into mice once a week, at a concentration of 50 mg/kg.
Immunostaining
Tumors were fixed in 4% PFA overnight, embedded into paraffin and sectioned into 5 μm sections. Tumor sections were subjected to H&E, or immunofluorescence staining, https://mediasrc.bcm.edu/documents/2014 /78/immunofluorescencegeneralprotocol.pdf, as per the protocol, and probed overnight at 4°C with antibodies for E-cadherin (Cell Signaling, 3195), keratin-14 (Covance, PRB-155P), keratin-8 (DSHB, Troma-1-c), Ki67 (Vector Labs, VP-K451), vimentin (Cell Signaling, 5741), Zeb1 (Cell Signaling, 3396), N-cadherin (Invitrogen, 333900), Snai2 (Cell Signaling, 9585), all diluted according to the manufacturer's instructions.
RNA isolation and qPCR
RNA was isolated using Qiagen microRNeasy kit (217084). cDNA was synthesized either using a High Capacity RNA to cDNA kit (Applied Biosystems, 4387406) or a microRNA kit (Applied Biosystems, 4366597). qPCR was performed with Taqman assays (Cdh1 Mm01247357_m1, Zeb1 Mm00495564_m1, Zeb2 Mm00497193_m1, Vimentin Mm01333430_m1, N-cadherin Mm01162497_m1, Snai2 Mm00441531_m1, Ezh2 Mm00468464_ m1, Bmi1 Mm03053308_m1, Gata3 Mm00484683_m1, Elf5 Mm00468732_ m1) on a Step One Plus real-time PCR machine.
Western blot and RPPA analysis Flash frozen tumor pieces or sorted cells were homogenized in RIPA buffer with added protease and phosphatase inhibitors (Roche) using a Polytron tissue homogenizer or vigorous pipetting. Protein concentrations were determined using a Bradford assay. Equal amounts of proteins were loaded onto a BioRad Pre-Cast gel, run at 100 V and subsequently transferred onto a poly(vinylidene fluoride) membrane. Blocking was performed in 5% non-fat dry milk diluted in Tris buffered saline/tween 20. Primary antibodies were diluted in 5% bovine serum albumin in Tris buffered saline/tween 20 and incubated overnight at 4°C. Protein bands were visualized on autoradiography films. RPPA analysis was performed in the core of Dr Gordon Mills at the MD Anderson Cancer Center.
Flow cytometry
Single cells were labeled with antibodies for CD24-PeCy7 and CD29-PacBlue, or Annexin V-PacBlue (BD Pharmingen), based on the manufacturer's data sheet. Lineage cells were excluded using the BD Pharmingen lineage cocktail. Dead cells were excluded by staining with Sytox Red (1:1000).
Microarray analysis
Microarray was performed and analyzed as previously described. 21 GEO accession number is GSE62230.
Statistical analysis
Each experiment was repeated a minimum of three times, with n ⩾ 3 biological replicates in each group, unless otherwise noted. Two-tailed paired Student's t-test was applied when only two groups were compared. Bars represent mean ± s.d. of ⩾ 3 mice per group (*P o0.05, **Po0.01, ***P o0.001). One-way analysis of variance with Tukey P-value adjustment was applied to multiple group comparisons.
